FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024001022> ?p ?o ?g. }

• W2024001022 endingPage "874" @default.
• W2024001022 startingPage "869" @default.
• W2024001022 abstract "To investigate whether recombinant human insulin-like growth factor-I (rhIGF-I) could serve as a protein-sparing nondiabetogenic agent, 21 healthy volunteers (mean age, 25 +/- 1 yr) were studied in 3 similar clinical models: rhIGF-I alone, rhIGF-I and prednisone, and prednisone alone. In study A, 6 subjects received infusions of [14C]leucine and [2H2]glucose before and after 5-7 days of rhIGF-I (100 micrograms/kg, sc, twice daily, followed by 16 h of a 10 micrograms/kg.h continuous sc infusion). The rate of appearance (Ra) of leucine, an estimate of whole body proteolysis, did not change significantly, whereas leucine oxidation decreased (-31 +/- 4%; P = 0.001), hence the nonoxidative leucine disposal (NOLD) increased significantly (P = 0.04). These effects are similar to those reported with high dose hGH. Plasma glucose concentrations did not change despite a significant reduction in circulating insulin concentrations (-58 +/- 11%; P = 0.01) and an increase in the glucose Ra (+12 +/- 5%; P = 0.04). After rhIGF-I treatment, plasma IGF-I, IGF-binding protein-1 (IGFBP-1), and IGFBP-2 all increased significantly, whereas IGFBP-3 did not change. In study B, seven subjects received rhIGF-I combined with oral prednisone (0.8 mg/kg.day) for 5 days. Group C (n = 8) received only prednisone. In group B, both the leucine Ra and oxidation increased (Ra, +7 +/- 3%; oxidation, +45 +/- 13%), but this increase was significantly less than that seen in group C (Ra, +25 +/- 5%; oxidation, 117 +/- 17%; P < 0.005 vs. group B). Group B showed no significant changes in postabsorptive glucose concentrations despite marked reductions in circulating insulin levels, in contrast to the increase in insulin and glucose concentrations observed in group C. In conclusion, 100 micrograms/g rhIGF-I, given twice daily, 1) has GH-like effects on whole body protein metabolism, 2) markedly diminishes the protein catabolic effect of glucocorticosteroids, and 3) is nondiabetogenic in prednisone-treated humans. This agent offers promise in the treatment of protein catabolic states." @default.
• W2024001022 created "2016-06-24" @default.
• W2024001022 creator A5043773015 @default.
• W2024001022 creator A5073479284 @default.
• W2024001022 date "1995-03-01" @default.
• W2024001022 modified "2023-10-03" @default.
• W2024001022 title "Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect." @default.
• W2024001022 cites W1754402125 @default.
• W2024001022 cites W1755863152 @default.
• W2024001022 cites W1846485537 @default.
• W2024001022 cites W1922578201 @default.
• W2024001022 cites W1940753119 @default.
• W2024001022 cites W1971147541 @default.
• W2024001022 cites W1984035921 @default.
• W2024001022 cites W1984178591 @default.
• W2024001022 cites W1985245731 @default.
• W2024001022 cites W2001241371 @default.
• W2024001022 cites W2005759424 @default.
• W2024001022 cites W2005928583 @default.
• W2024001022 cites W2006156624 @default.
• W2024001022 cites W2010801315 @default.
• W2024001022 cites W2020151384 @default.
• W2024001022 cites W2025421578 @default.
• W2024001022 cites W2026144395 @default.
• W2024001022 cites W2029951747 @default.
• W2024001022 cites W2048422282 @default.
• W2024001022 cites W2081096579 @default.
• W2024001022 cites W2091395937 @default.
• W2024001022 cites W2100376198 @default.
• W2024001022 cites W2105710561 @default.
• W2024001022 cites W2119891717 @default.
• W2024001022 cites W2134758256 @default.
• W2024001022 cites W2146557873 @default.
• W2024001022 cites W2159028819 @default.
• W2024001022 cites W2202771518 @default.
• W2024001022 cites W2336816988 @default.
• W2024001022 cites W2344436976 @default.
• W2024001022 cites W2419411791 @default.
• W2024001022 cites W2427857930 @default.
• W2024001022 cites W284497110 @default.
• W2024001022 cites W3023791058 @default.
• W2024001022 cites W348706318 @default.
• W2024001022 doi "https://doi.org/10.1210/jcem.80.3.7533772" @default.
• W2024001022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7533772" @default.
• W2024001022 hasPublicationYear "1995" @default.
• W2024001022 type Work @default.
• W2024001022 sameAs 2024001022 @default.
• W2024001022 citedByCount "32" @default.
• W2024001022 countsByYear W20240010222016 @default.
• W2024001022 countsByYear W20240010222022 @default.
• W2024001022 countsByYear W20240010222023 @default.
• W2024001022 crossrefType "journal-article" @default.
• W2024001022 hasAuthorship W2024001022A5043773015 @default.
• W2024001022 hasAuthorship W2024001022A5073479284 @default.
• W2024001022 hasConcept C1008401 @default.
• W2024001022 hasConcept C104317684 @default.
• W2024001022 hasConcept C126322002 @default.
• W2024001022 hasConcept C134018914 @default.
• W2024001022 hasConcept C170493617 @default.
• W2024001022 hasConcept C185592680 @default.
• W2024001022 hasConcept C197683979 @default.
• W2024001022 hasConcept C2775960820 @default.
• W2024001022 hasConcept C2776580952 @default.
• W2024001022 hasConcept C2778720950 @default.
• W2024001022 hasConcept C2779306644 @default.
• W2024001022 hasConcept C2780689927 @default.
• W2024001022 hasConcept C40767141 @default.
• W2024001022 hasConcept C515207424 @default.
• W2024001022 hasConcept C55493867 @default.
• W2024001022 hasConcept C62231903 @default.
• W2024001022 hasConcept C71924100 @default.
• W2024001022 hasConcept C96942376 @default.
• W2024001022 hasConceptScore W2024001022C1008401 @default.
• W2024001022 hasConceptScore W2024001022C104317684 @default.
• W2024001022 hasConceptScore W2024001022C126322002 @default.
• W2024001022 hasConceptScore W2024001022C134018914 @default.
• W2024001022 hasConceptScore W2024001022C170493617 @default.
• W2024001022 hasConceptScore W2024001022C185592680 @default.
• W2024001022 hasConceptScore W2024001022C197683979 @default.
• W2024001022 hasConceptScore W2024001022C2775960820 @default.
• W2024001022 hasConceptScore W2024001022C2776580952 @default.
• W2024001022 hasConceptScore W2024001022C2778720950 @default.
• W2024001022 hasConceptScore W2024001022C2779306644 @default.
• W2024001022 hasConceptScore W2024001022C2780689927 @default.
• W2024001022 hasConceptScore W2024001022C40767141 @default.
• W2024001022 hasConceptScore W2024001022C515207424 @default.
• W2024001022 hasConceptScore W2024001022C55493867 @default.
• W2024001022 hasConceptScore W2024001022C62231903 @default.
• W2024001022 hasConceptScore W2024001022C71924100 @default.
• W2024001022 hasConceptScore W2024001022C96942376 @default.
• W2024001022 hasIssue "3" @default.
• W2024001022 hasLocation W20240010221 @default.
• W2024001022 hasLocation W20240010222 @default.
• W2024001022 hasOpenAccess W2024001022 @default.
• W2024001022 hasPrimaryLocation W20240010221 @default.
• W2024001022 hasRelatedWork W1968380023 @default.
• W2024001022 hasRelatedWork W1979390191 @default.
• W2024001022 hasRelatedWork W1991453182 @default.

• next